Treatment Results of Radiation Therapy for Muscle-Invasive Bladder Cancer

Abstract

Radiotherapy is an effective treatment option in terms of local control and survival even in elderly patients with locally advanced bladder cancer not suitable for cystectomy.

Radiotherapy in localized bladder cancer: what is the evidence?

“…A majority of patients were diagnosed with cT3þ disease clinically, although stage did not correlate with outcome in this small study. A complete response was seen in 65% and after 3 years 52% maintained local control; however, 35% of patients died from bladder cancer [18 ].…”

Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy

“…The obtained outcomes are more favorable as compared to conventionally fractionated radiotherapy used in the treatment of invasive bladder cancer. [8][9][10][11] Radical radiotherapy for invasive bladder cancer using hypofractioned regimens of total dose of 52.5-57.5 Gy in 20 daily fractions of 2.6-2.9 Gy is a widespread approach in the United Kingdom. Presented hypofractionated and conventionally fractionated (60-64 Gy in 30-32 daily fractions) radiation schedules are equivalent in terms of toxicity, both acute and late, and treatment results.…”

“…[4][5][6][7] In patients who underwent local conservative treatment, that is TURB followed by radiotherapy, the 5-year overall and disease-specific survival rates were 20-40% and 31-56.8%, respectively. [8][9][10][11] As the cure rates offered by local conservative treatment are significantly inferior to those offered by trimodality bladder-preserving therapies, this approach is used exclusively for patients with MIBC who have to be excluded from chemotherapy for medical reasons. However, the demand for local treatment, involving TURB and radiotherapy, is increasing worldwide especially for the group of elderly patients, with significant co-morbidities.…”

A feasibility study of transurethral resection followed by radiotherapy combined with concurrent twice-weekly gemcitabine in the treatment of invasive bladder carcinoma

“…These results are comparable to Lin et al [22] who reported DFS 54% at 3 years. Langsenhner et al [23] and Maarouf et al [24] reported 40% at 3 years and 39% at 1 year respectively. However those are lower than it was reported by Rincon et al [2] who reported PFS 69% at 3 years, but their protocol was used adjuvant 2-4 cycle of chemotherapy, (taxol, methotrexate, 5 FU, and cisplatin).…”